Marina D. Kaymakcalan
Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Renal and related cancers, Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics
Most-Cited Works
- → Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway(2014)203 cited
- → Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma(2015)133 cited
- → QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors(2014)129 cited
- → Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma(2019)94 cited
- → Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study(2015)90 cited
- → Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma(2020)83 cited
- → Adrenocortical carcinoma: The management of metastatic disease(2014)69 cited
- → Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma(2020)68 cited
- → Statins and survival outcomes in patients with metastatic renal cell carcinoma(2015)46 cited
- → Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma(2017)43 cited